No Net Benefit from Adding Antiplatelet Therapy to Anticoagulation After Ischemic Stroke With Atrial Fibrillation and Atherosclerosis — Higher Bleeding Risk

No Net Benefit from Adding Antiplatelet Therapy to Anticoagulation After Ischemic Stroke With Atrial Fibrillation and Atherosclerosis — Higher Bleeding Risk

In a randomized trial of 316 patients with ischemic stroke/TIA, nonvalvular atrial fibrillation, and atherosclerotic disease, adding an antiplatelet to anticoagulation did not reduce ischemic events but doubled clinically relevant bleeding compared with anticoagulant monotherapy.
Tirzepatide Lowers 10‑Year Predicted Risk of Cardiovascular Disease and Type 2 Diabetes in Adults with Obesity and Prediabetes: Post hoc Analysis of SURMOUNT‑1

Tirzepatide Lowers 10‑Year Predicted Risk of Cardiovascular Disease and Type 2 Diabetes in Adults with Obesity and Prediabetes: Post hoc Analysis of SURMOUNT‑1

A post hoc analysis of the three‑year SURMOUNT‑1 trial found that once‑weekly tirzepatide (5–15 mg) produced dose‑dependent reductions in 10‑year predicted risks for ASCVD, heart failure, total CVD and progression to type 2 diabetes versus placebo in adults with obesity and prediabetes.
EAT‑Lancet Diet and Recurrent Cardiovascular Events: Lower Stroke Risk and a Signal for Myocardial Infarction in Patients with Established CVD

EAT‑Lancet Diet and Recurrent Cardiovascular Events: Lower Stroke Risk and a Signal for Myocardial Infarction in Patients with Established CVD

Two cohort analyses suggest greater adherence to the EAT‑Lancet diet is linked with lower recurrent non‑fatal vascular events—notably stroke—and that education and sex modify long‑term cardioprotective benefits of this sustainable, plant‑forward pattern.
Immediate Coronary Angiography After Out‑of‑Hospital Cardiac Arrest Without ST Elevation Shows No 1‑Year Survival Benefit — IPD Meta‑Analysis of COACT and TOMAHAWK

Immediate Coronary Angiography After Out‑of‑Hospital Cardiac Arrest Without ST Elevation Shows No 1‑Year Survival Benefit — IPD Meta‑Analysis of COACT and TOMAHAWK

An individual patient data meta‑analysis of COACT and TOMAHAWK (n=1,031) found no 1‑year survival benefit to immediate coronary angiography versus delayed/selective angiography after out‑of‑hospital cardiac arrest (OHCA) without ST‑elevation; no patient subgroup showed a clear differential benefit.
LMNA Variant Type and Location Shape Arrhythmic Risk in Cardiomyopathy: Truncations Confer Higher VA Risk; Tail-domain Missense Variants Appear Lower Risk

LMNA Variant Type and Location Shape Arrhythmic Risk in Cardiomyopathy: Truncations Confer Higher VA Risk; Tail-domain Missense Variants Appear Lower Risk

In 718 patients with pathogenic/likely pathogenic LMNA variants, truncating variants carried higher risk of malignant ventricular arrhythmia independent of position, while missense variants in the tail domain and exons 7–12 had lower arrhythmic and heart-failure events, suggesting genotype-location refines risk stratification.